Related Experiment Video
Updated: May 3, 2026

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
Published on: March 8, 2024
[Prolonged phase II neuromuscular blockade following succinylcholine administration]
G Jurkolow1, T Fuchs-Buder1, A Lemoine1
1Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
Abstract:
Patients who are given a single dose of succinylcholine normally undergo a short-acting depolarizing phase I neuromuscular block but rarely a phase II block. Prolonged neuromuscular blockade occurs after a single dose of succinylcholine in case of genetically determined abnormal plasma butyrylcholinesterase activity. It is mandatory to use monitoring to detect this side effect. We report a case of a patient with abnormal plasma butyrylcholinesterase activity undergoing a six-hour prolonged neuromuscular phase II block, after a single dose of succinylcholine.
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Skeletal Muscle Relaxants: Therapeutic Uses

